Form 8-K Keros Therapeutics, Inc. For: Jul 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Keros Therapeutics CFO resigns, interim finance chief named
July 22, 2026 4:05 PM EDTKeros Therapeutics (NASDAQ: KROS) announced that Keith Regnante resigned as Chief Financial Officer, effective August 3, 2026, to pursue other opportunities. The company stated his departure was voluntary and not the result of any disagreement over accounting practices, financial statements, internal controls, or company policies.
The company's Board of Directors appointed Annita... More
